Industry News

Pharma Courses 
PAGE Admission
  • Aino Health is approved by Swedish Social Insurance Agency as a workplace-oriented rehabilitation support organizer
    22 October 2021

    Aino Health is approved by Swedish Social Insurance Agency as a workplace-oriented rehabilitation support organizer

    Swedish Social Insurance Agency (Försäkringskassan), has granted Aino Health approval to provide proactive and rehabilitative efforts in the workplace. In collaboration with Swedish Social Insurance Agency, Aino Health can offer support investigating, planning, implementing and following up on work-oriented measures.  

    The purpose of the grant is to prevent sick leave and make it easier for employees to return to work after sick leave. 

  • 22 October 2021
    Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

    PARIS and TARRYTOWN, N.Y. – October 22, 2021 - A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease that causes extreme itch and skin lesions, met its primary and all key secondary endpoints, showing that Dupixent significantly reduced itch and skin lesions compared to placebo in this investigational setting. The impact of uncontrolled prurigo nodularis on quality of life is one of the highest among inflammatory skin diseases with intense, chronic itch.

  • 21 October 2021
    LumiraDx receives approval for its COVID-19 Antigen Test for use in India

    LumiraDx a next-generation point of care diagnostics testing company announced it has received emergency use approval by India’s Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.

  • 21 October 2021
    Amgen Successfully Completes Acquisition Of Teneobio, Inc

    Amgen announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective as of Oct. 19, 2021, Amgen has acquired all outstanding equity of Teneobio in exchange for a USD 900 million upfront cash payment, as well as future contingent milestone payments, to former Teneobio equity holders potentially worth up to an additional USD 1.6 billion in cash.

  • 19 October 2021
    Dr. Reddys Laboratories announces approval for Lenalidomide Capsules from the USFDA

    Dr. Reddys Laboratories Ltd announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules, from the U.S. Food and Drug Administration (USFDA). With this approval, Dr. Reddy’s is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.

  • 12 October 2021
    Covaxin get emergency approval for children aged 2-18 years

    The Subject Expert Committee (SEC) of CDSCO has granted emergency use approval (EUA) to Covaxin for children in the 2-18 years age group. Covaxin is developed by Hyderabad based Bharat Biotech.

    Caovaxin had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the Drugs Controller General of India (DCGI) at the start of this month.

  • 11 October 2021
    Sandoz acquire cephalosporin business of GSK

     Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.

    Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

  • 11 October 2021
    OSE Immunotherapeutics receives European patent for Tedopi, cancer vaccine

    OSE Immunotherapeutics SA announced that it has received notice of allowance from the European Patent Office for a patent application related to Tedopi®, a neoepitope therapeutic vaccine, protecting a method for manufacturing a ready-to-use peptide emulsion for its use in the treatment of cancers in HLA-A2 positive patients. This patent will provide a protection until 2038.

  • 11 October 2021
    BRUKINSA approved for treatment of Patients with Mantle Cell Lymphoma

    BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

  • 2 October 2021
    Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

    Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

    The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

Subscribe to Industry News